Odronextamab demonstrated a 48.3% objective response rate ... this is the first analysis demonstrating T-cell fitness during treatment with a CD20×CD3 bispecific antibody.” Between May 17, 2020, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback